The current status on the use of biopharmaceuticals in the treatment of rheumatoid arthritis is reviewed. Blocking of TNF-alpha, co-stimulation of CD28+ T-cells and depletion of CD20+ B-cells are all effective ways to diminish inflammation and joint damage. However, not all patients react to these treatments, and the development of biomarkers to predict which patients will benefit from these drugs is therefore warranted.
|Translated title of the contribution||[Biopharmaceuticals in the treatment of rheumatoid arthritis]|
|Journal||Ugeskrift for Laeger|
|Number of pages||3|
|Publication status||Published - 9 Jun 2008|